Elenbecestat

DB15391InvestigationalSmall molecule

Elenbecestat is under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease).

Mechanism: Pharmacologically active on Beta-secretase 1
Curator reviewed
Formula / weight: C₁₉H₁₈F₃N₅O₂S · 437.44 g/mol (avg)

Resolves to

Compound

UNIIRXJ96XL94HCAS1388651-30-6

Structure

InChIKeyAACUJFVOHGRMTR-DPXNYUHVSA-NSMILESC[C@H]1OC[C@@]2(N=C(N)SC[C@H]12)C1=CC(NC(=O)C2=NC=C(N=C2)C(F)F)=CC=C1F

Targets

P56817BACE1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Elenbecestat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account